GRI Bio Stock Price, News & Analysis

GRI Bio (NASDAQ: GRI) reported year-end $8.2 million in cash and cash equivalents as of December 31, 2025 and raised an additional $6.5 million in January 2026, strengthening the balance sheet to fund operations into Q1 2027. Key clinical highlights include positive Phase 2a topline data for GRI-0621 in idiopathic pulmonary fibrosis, supplemental RNA‑seq and immune phenotype data reinforcing proof‑of‑concept, and advancement of GRI-0803 toward IND‑enabling studies for autoimmune indications.

GRI Bio (NASDAQ: GRI) reported new Phase 2a RNA‑sequencing data for GRI-0621 in idiopathic pulmonary fibrosis (IPF) showing significant differential gene expression across pathways linked to lung injury, myofibroblast activation, extracellular matrix deposition, and alveolar basement membrane and epithelial repair versus placebo.

These gene expression changes align with earlier biomarker and immune phenotype signals—reduced neutrophil activity, increased fibrillar collagen degradation, and lower pro‑fibrotic cytokines—and support a mechanism consistent with fibrosis resolution and alveolar regeneration. The study met its primary safety endpoint, showed multiple secondary signs of disease‑modifying activity, and reported exploratory FVC benefit at 12 weeks.

GRI Bio (NASDAQ: GRI) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,528,775 on January 26, 2026, granting composition-of-matter claims for a distinct class of proprietary compounds.

The patent covers linked molecular structures that form pyrrolidine, piperidine, or azepane ring systems, which the company says are separate from prior patents and strengthen its intellectual property estate. The issuance supports GRI Bio’s platform targeting NKT cell biology and complements its lead program GRI-0621 and a chemistry library of over 500 proprietary compounds.

GRI Bio (NASDAQ: GRI) announced a 1-for-28 reverse stock split, effective 4:01 p.m. ET on January 23, 2026, with post-split trading to begin on a split-adjusted basis on The Nasdaq Capital Market on January 26, 2026 under the ticker GRI and new CUSIP 3622AW502.

The reverse split reduces outstanding shares from ~15,016,434 to ~536,301 and is intended to help the company regain compliance with Nasdaq's minimum bid price requirement. Fractional shares will be paid in cash based on the closing price on January 23, 2026. Proportional adjustments will apply to options, warrants, convertible securities, and incentive plan shares.

GRI Bio (NASDAQ: GRI) reported positive Phase 2a flow cytometry data for GRI-0621 in idiopathic pulmonary fibrosis (IPF). After 12 weeks, treated subjects showed iNKT inhibition, increased TCR expression, higher anti-fibrotic IFN-γ and reductions in IL-4, IL-13, IL-17A, IL-22 and TGF-β in BAL and PBMC samples versus baseline or placebo.

The randomized, double-blind 2:1 study enrolled 35 subjects (4.5mg daily or placebo) with an 8-subject BAL sub-study. The trial met its primary safety/tolerability endpoint and reported exploratory signals of collagen turnover, lung repair and more subjects with no FVC decline at 12 weeks versus standard of care. Company completed a December 2025 public offering and reports stockholders' equity above the Nasdaq $2.5M minimum.

GRI Bio (NASDAQ: GRI) closed a public offering on Dec 12, 2025 of 10,666,667 common shares (or equivalents) with accompanying Series F warrants at a combined public offering price of $0.75 per share and warrant.

Aggregate gross proceeds to the company were approximately $8.0 million before placement agent fees and offering expenses. The Series F warrants are exercisable immediately at $0.75 per share, expire five years after issuance, and could generate approximately $8.0 million additional gross proceeds if fully exercised. H.C. Wainwright acted as exclusive placement agent. The company intends to use net proceeds for product candidate development, working capital and general corporate purposes. The offering was made under an S-1 declared effective by the SEC on Dec 11, 2025.

GRI Bio (NASDAQ: GRI) priced a best efforts public offering of 10,666,667 common shares (or equivalents) and accompanying Series F warrants at a combined public offering price of $0.75 per share with attached warrant. The Series F Warrants have a $0.75 exercise price, are exercisable immediately and expire five years after issuance. Closing is expected on or about December 12, 2025. Gross proceeds are expected to be approximately $8,000,000, with potential additional proceeds of approximately $8,000,000 if warrants are fully exercised. Proceeds are intended for product candidate development, working capital and general corporate purposes. The offering is made under an effective Form S-1 declared by the SEC on December 11, 2025.

GRI Bio (NASDAQ: GRI) announced positive topline results from its Phase 2a GRI-0621-IPF-02 study in idiopathic pulmonary fibrosis (IPF) on December 10, 2025. The 12-week, randomized (2:1), placebo-controlled trial enrolled 35 subjects and met its primary safety endpoint with no drug-related severe or serious adverse events.

Key secondary and exploratory findings included biomarker shifts consistent with fibrosis resolution and alveolar basement membrane repair (PRO-C6 -3% vs +12% placebo; C6M +6% vs -3% placebo; PRO-C4 +9% vs -2% placebo) and placebo-adjusted increases in forced vital capacity (+99 ml overall; +139 ml in the subgroup on standard of care). Overall, 39% of GRI-0621 subjects had increased FVC at 12 weeks.

GRI Bio (NASDAQ: GRI) has reported encouraging 6-week interim lung function data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The data showed no decline in forced vital capacity (FVC) at 6 weeks compared to baseline in treated patients.

The study, involving 24 subjects, demonstrated positive biomarker changes suggesting anti-fibrotic effects, including decreased fibrosis formation markers and increased fibrosis resolution markers. The Independent Data Monitoring Committee (IDMC) reported no safety concerns and recommended continuing the study as planned.

The Phase 2a trial has fully enrolled approximately 35 subjects, randomized 2:1 to receive GRI-0621 4.5mg or placebo. Topline results are expected in Q3 2025.